Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib

Experimental Hematology

Volumn 42, Issue 6, 2014, Pages 439-447

  Glodkowska Mrowka, Eliza ^a   Mrowka, Piotr ^a   Basak, Grzegorz W ^a   Niesiobedzka Krezel, Joanna ^a   Seferynska, Ilona ^b   Wlodarski, Pawel Krzysztof ^a   Jakobisiak, Marek ^a   Stoklosa, Tomasz ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ABELSON KINASE 1; ATORVASTATIN; BREAKPOINT CLUSTER REGION PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CARBON 14; CERIVASTATIN; FLUINDOSTATIN; IMATINIB; MEVINOLIN; MULTIDRUG RESISTANCE PROTEIN 1; OCTAMER TRANSCRIPTION FACTOR 1; SIMVASTATIN; UNCLASSIFIED DRUG;

ABCB1 GENE; ABCG2 GENE; ANTILEUKEMIC ACTIVITY; APOPTOSIS; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENTIATION; DRUG TRANSPORT; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN DEPLETION;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BENZAMIDES; BLOTTING, WESTERN; CELL LINE; CELL SURVIVAL; DRUG SYNERGISM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; K562 CELLS; LEUKEMIA, MYELOID, CHRONIC-PHASE; LOVASTATIN; MICE; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PIPERAZINES; PYRIMIDINES;

EID: 84902687044     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2014.02.006     Document Type: Article

References (29)

1. Rowley J.D. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290-293.
2. O'Hare T., Deininger M.W., Eide C.A., Clackson T., Druker B.J. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res 2011, 17:212-221.
3. Koptyra M., Falinski R., Nowicki M.O., et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006, 108:319-327.
4. Groarke J.D., Cheng S., Moslehi J. Cancer-drug discovery and cardiovascular surveillance. N Engl J Med 2013, 369:1779-1781.
5. Apperley J.F. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007, 8:1018-1029.
6. Thomas J., Wang L., Clark R.E., Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004, 104:3739-3745.
7. Nies A.T., Schaeffeler E., van der Kuip H., et al. Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). Clin Cancer Res 2014, 20:985-994.
8. Houghton P.J., Germain G.S., Harwood F.C., et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 invitro. Cancer Res 2004, 64:2333-2337.
9. Jordanides N.E., Jorgensen H.G., Holyoake T.L., Mountford J.C. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 2006, 108:1370-1373.
10. Dohse M., Scharenberg C., Shukla S., et al. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos 2010, 38:1371-1380.
11. Shukla S., Sauna Z.E., Ambudkar S.V. Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2. Leukemia 2008, 22:445-447.
12. Hiwase D.K., White D., Zrim S., Saunders V., Melo J.V., Hughes T.P. Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy. Leukemia 2010, 24:658-660.
13. White D.L., Eadie L.N., Saunders V.A., Hiwase D.K., Hughes T.P. Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells. Leukemia 2013, 27:1201-1204.
14. Eadie L.N., Hughes T.P., White D.L. The Interaction of Efflux Transporters, ABCB1 and ABCG2, with Imatinib, Nilotinib and Dasatinib. Clin Pharmacol Ther 2014, 95:294-306.
15. Winiarska M., Bil J., Wilczek E., et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 2008, 5:e64.
16. Malenda A., Skrobanska A., Issat T., et al. Statins impair glucose uptake in tumor cells. Neoplasia 2012, 14:311-323.
17. Telbisz A., Muller M., Ozvegy-Laczka C., et al. Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter. Biochim Biophys Acta 2007, 1768:2698-2713.
18. Telbisz A., Ozvegy-Laczka C., Hegedus T., Varadi A., Sarkadi B. Effects of the lipid environment, cholesterol and bile acids on the function of the purified and reconstituted human ABCG2 protein. Biochem J 2013, 450:387-395.
19. Eckford P.D., Sharom F.J. Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport. Biochemistry 2008, 47:13686-13698.
20. Goard C.A., Mather R.G., Vinepal B., et al. Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents. Int J Cancer 2010, 127:2936-2948.
21. Jakobisiak M., Golab J. Statins can modulate effectiveness of antitumor therapeutic modalities. Med Res Rev 2010, 30:102-135.
22. Feleszko W., Mlynarczuk I., Balkowiec-Iskra E.Z., et al. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin Cancer Res 2000, 6:2044-2052.
23. Chen R., Xiao W., Li D., Mu S. Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death. Med Oncol 2011, 28:528-531.
24. Nieborowska-Skorska M., Kopinski P.K., Ray R., et al. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood 2012, 119:4253-4263.
25. Oh B., Kim T.Y., Min H.J., et al. Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells. Anticancer Drugs 2013, 24:20-31.
26. Lipka D.B., Wagner M.C., Dziadosz M., et al. Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells. PLoS One 2012, 7:e40853.
27. Perrotti D., Jamieson C., Goldman J., Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 2010, 120:2254-2264.
28. Aichberger K.J., Herndlhofer S., Schernthaner G.H., et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011, 86:533-539.
29. Kim T.D., Rea D., Schwarz M., et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 2013, 27:1316-1321.